Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
le Roux CW, Wharton S, Bozkurt B, et al.
Diabetes Obes Metab. Pub. online 4 Nov 2025.
Leggi


